The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Agilon Health Inc (NYSE: AGL) closed the day trading at $0.66 up 3.94% from the previous closing price of $0.64. In other words, the price has increased by $3.94 from its previous closing price. On the day, 6.91 million shares were traded. AGL stock price reached its highest trading level at $0.6722 during the session, while it also had its lowest trading level at $0.6298.
Ratios:
For a better understanding of AGL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.08 and its Current Ratio is at 1.08. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 06, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $1.
Citigroup Upgraded its Neutral to Buy on April 25, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when McLoughlin Karen bought 25,000 shares for $2.20 per share. The transaction valued at 55,085 led to the insider holds 73,166 shares of the business.
Battaglia Silvana bought 25,062 shares of AGL for $50,269 on Dec 11 ’24. The Director now owns 66,144 shares after completing the transaction at $2.01 per share. On Dec 09 ’24, another insider, MCKENZIE DIANA, who serves as the Director of the company, bought 7,500 shares for $2.20 each. As a result, the insider paid 16,489 and bolstered with 58,819 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 275406560 and an Enterprise Value of 1673559. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.05 while its Price-to-Book (P/B) ratio in mrq is 0.90. Its current Enterprise Value per Revenue stands at 0.0 whereas that against EBITDA is -0.005.
Stock Price History:
The Beta on a monthly basis for AGL is 0.08, which has changed by -0.68229663 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $6.08, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is -24.18%, while the 200-Day Moving Average is calculated to be -70.85%.
Shares Statistics:
Over the past 3-months, AGL traded about 8.87M shares per day on average, while over the past 10 days, AGL traded about 12819130 shares per day. A total of 414.57M shares are outstanding, with a floating share count of 304.79M. Insiders hold about 26.48% of the company’s shares, while institutions hold 68.72% stake in the company. Shares short for AGL as of 1763078400 were 20803215 with a Short Ratio of 2.34, compared to 1760486400 on 20402280. Therefore, it implies a Short% of Shares Outstanding of 20803215 and a Short% of Float of 8.1999995.
Earnings Estimates
. The current market rating for Agilon Health Inc (AGL) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.04, with high estimates of $0.02 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.4 and -$0.85 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.42, with 13.0 analysts recommending between -$0.33 and -$0.52.
Revenue Estimates
15 analysts predict $1.46B in revenue for. The current quarter. It ranges from a high estimate of $1.54B to a low estimate of $1.42B. As of. The current estimate, Agilon Health Inc’s year-ago sales were $1.52BFor the next quarter, 15 analysts are estimating revenue of $1.59B. There is a high estimate of $1.67B for the next quarter, whereas the lowest estimate is $1.5B.
A total of 17 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $5.9B, while the lowest revenue estimate was $5.78B, resulting in an average revenue estimate of $5.83B. In the same quarter a year ago, actual revenue was $6.06BBased on 17 analysts’ estimates, the company’s revenue will be $6.04B in the next fiscal year. The high estimate is $6.41B and the low estimate is $5.51B.
